Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adagloxad simolenin - OBI Pharma

Drug Profile

Adagloxad simolenin - OBI Pharma

Alternative Names: Adagloxad simolenin; Cancer vaccine Globo-H; Globo H-KLH; Globo-H vaccine; OBI-822; OBI-822/OBI-821; OPT-22; OPT-822/821; OPT-822/OPT-821

Latest Information Update: 05 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; OBI Pharma
  • Class Antineoplastics; Cancer vaccines; Conjugate vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Fallopian tube cancer; Neuroblastoma; Ovarian cancer; Peritoneal cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 21 Sep 2023 Phase-II clinical trials in Neuroblastoma (Combination therapy, In children, In adults, In the elderly) in USA (SC) (NCT06057948)
  • 01 Jul 2022 OBI Pharma plans a phase II trial for non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in June 2022 (SC) (NCT05442060)
  • 05 Apr 2021 Adagloxad simolenin is still in phase III trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT03562637)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top